HSPA1A and neoplasm: For example, multiple lines of evidence, including our own, have demonstrated that Hsp70 inhibitors in combination regimens markedly enhance the sensitivity of various tumor cell types to conventional therapies such as doxorubicin, etoposide, and bortezomib, both in vitro and in vivo [20,21,22,23].